Last $86.67 USD
Change Today +1.09 / 1.27%
Volume 925.7K
MDVN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 5:20 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (MDVN) Snapshot

Open
$85.66
Previous Close
$85.58
Day High
$87.15
Day Low
$85.07
52 Week High
02/25/14 - $88.20
52 Week Low
10/22/13 - $48.15
Market Cap
6.7B
Average Volume 10 Days
1.3M
EPS TTM
$0.27
Shares Outstanding
76.8M
EX-Date
07/27/99
P/E TM
321.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (MDVN)

medivation inc (MDVN) Related Businessweek News

No Related Businessweek News Found

medivation inc (MDVN) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

433 Employees
Last Reported Date: 08/7/14

medivation inc (MDVN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $750.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $480.4K
Chief Compliance Officer, General Counsel and...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

medivation inc (MDVN) Key Developments

Medivation, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2014

Medivation, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced the company announced collaboration revenue of $148,090,000 compared to $70,149,000 for the same period a year ago. Income from operations was $54,951,000 compared to $54,000 for the same period a year ago. Income before income tax was $49,530,000 compared to loss before tax of $4,866,000 for the same period a year ago. Net income was $47,919,000 compared to net loss of $4,898,000 for the same period a year ago. Diluted net income per common share was $0.60 compared to loss per share of $0.07 for the same period a year ago. For the six months, the company announced the company announced collaboration revenue of $235,279,000 compared to $116,303,000 for the same period a year ago. Income from operations was $46,486,000 compared to loss from operations of $22,268,000 for the same period a year ago. Income before income tax was $35,806,000 compared to loss before tax of $32,003,000 for the same period a year ago. Net income was $34,254,000 compared to net loss of $32,068,000 for the same period a year ago. Diluted net income per common share was $0.43 compared to loss per share of $0.43 for the same period a year ago. For the full year 2014, the company expects U.S. net sales of XTANDI to be between $600 million and $640 million, total collaboration revenue will range between $615 million to $640 million, which includes collaboration revenue related to U.S. net sales between $300 million and $320 million and collaboration revenue related to upfront and milestone payments of approximately $279 million.

Medivation, Inc., Q2 2014 Earnings Call, Aug 07, 2014

Medivation, Inc., Q2 2014 Earnings Call, Aug 07, 2014

Medivation, Inc. to Report Q2, 2014 Results on Aug 07, 2014

Medivation, Inc. announced that they will report Q2, 2014 results After-Market on Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDVN:US $86.67 USD +1.09

MDVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Insys Therapeutics Inc $34.14 USD -1.24
InterMune Inc $54.10 USD -0.43
Pfizer Ltd/India 1,369 INR -14.30
Sanofi India Ltd 3,092 INR +17.55
Seattle Genetics Inc $42.99 USD -0.27
View Industry Companies
 

Industry Analysis

MDVN

Industry Average

Valuation MDVN Industry Range
Price/Earnings 100.0x
Price/Sales 16.7x
Price/Book 45.8x
Price/Cash Flow 277.2x
TEV/Sales 15.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.